ITPA genotyping test does not improve defection of Crohn's disease patients at risk of azathioprine/6-mercaptopurine induced myelosuppression [1]

Gut

Volumn 54, Issue 4, 2005, Pages 565-

  Allorge, D ^a   Hamdan, R ^a   Broly, F ^a   Libersa, C ^b   Colombel, J F ^b  

^a UNIV LILLE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; INORGANIC PYROPHOSPHATASE; INOSINE TRIPHOSPHATE PYROPHOSPHATASE; MERCAPTOPURINE; UNCLASSIFIED DRUG;

BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CORRELATION ANALYSIS; CROHN DISEASE; DRUG DOSE REDUCTION; ENZYME DEFICIENCY; FLU LIKE SYNDROME; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HIGH RISK PATIENT; HOMOZYGOTE; HUMAN; LETTER; LEUKOPENIA; MISSENSE MUTATION; NEUTROPENIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SIDE EFFECT;

6-MERCAPTOPURINE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AZATHIOPRINE; CROHN DISEASE; DRUG THERAPY, COMBINATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOPENIA; PYROPHOSPHATASES;

EID: 15444367938     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2004.055947     Document Type: Letter

References (3)

1. Sumi S, Marinaki AM, Arenas M, et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum Genet 2002;111:360-7.
2. Marinaki AM, Ansari A, Duley JA, et al. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 2004;14:181-7.
3. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000;118:1025-30.